Calithera Biosciences (CALA) Competitors $0.0001 0.00 (-50.00%) As of 09/11/2025 03:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CALA vs. AMPE, HSTO, PXMD, CLVR, EFTR, ONCSQ, ATNFW, LBPSW, AEHAW, and AIMDWShould you be buying Calithera Biosciences stock or one of its competitors? The main competitors of Calithera Biosciences include Ampio Pharmaceuticals (AMPE), Histogen (HSTO), PaxMedica (PXMD), Clever Leaves (CLVR), eFFECTOR Therapeutics (EFTR), OncoSec Medical (ONCSQ), 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), and Ainos (AIMDW). These companies are all part of the "pharmaceutical products" industry. Calithera Biosciences vs. Its Competitors Ampio Pharmaceuticals Histogen PaxMedica Clever Leaves eFFECTOR Therapeutics OncoSec Medical 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Ampio Pharmaceuticals (NYSE:AMPE) and Calithera Biosciences (NASDAQ:CALA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment. Do insiders & institutionals have more ownership in AMPE or CALA? 5.7% of Ampio Pharmaceuticals shares are held by institutional investors. 3.3% of Ampio Pharmaceuticals shares are held by insiders. Comparatively, 6.6% of Calithera Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media favor AMPE or CALA? In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score. Company Overall Sentiment Ampio Pharmaceuticals Neutral Calithera Biosciences Neutral Is AMPE or CALA more profitable? Company Net Margins Return on Equity Return on Assets Ampio PharmaceuticalsN/A N/A N/A Calithera Biosciences N/A N/A N/A Which has more volatility & risk, AMPE or CALA? Ampio Pharmaceuticals has a beta of 5.09, meaning that its share price is 409% more volatile than the S&P 500. Comparatively, Calithera Biosciences has a beta of -2.55, meaning that its share price is 355% less volatile than the S&P 500. Which has higher valuation & earnings, AMPE or CALA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmpio PharmaceuticalsN/AN/A-$8.63M-$11.010.00Calithera BiosciencesN/AN/A-$39.65MN/AN/A SummaryAmpio Pharmaceuticals beats Calithera Biosciences on 3 of the 4 factors compared between the two stocks. Get Calithera Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart CALA vs. The Competition Export to ExcelMetricCalithera BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$861.40M$5.80B$10.16BDividend YieldN/A4.84%5.69%4.61%P/E RatioN/A1.1674.7325.99Price / SalesN/A26.72470.3491.76Price / CashN/A19.5637.0859.91Price / BookN/A6.7712.256.31Net Income-$39.65M-$4.20M$3.28B$270.66M7 Day PerformanceN/A7.88%1.39%3.52%1 Month PerformanceN/A11.04%7.70%6.79%1 Year PerformanceN/A25.68%64.01%28.29% Calithera Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALACalithera BiosciencesN/A$0.00-50.0%N/A-99.8%$0.00N/A0.0060Gap DownAMPEAmpio PharmaceuticalsN/A$0.00-96.8%N/A+22.7%$3KN/A0.0020Gap DownHSTOHistogenN/A$0.00+66.7%N/A-99.9%$2K$19K0.0020Gap UpPXMDPaxMedicaN/A$0.00flatN/AN/A$2KN/A0.002CLVRClever LeavesN/A$0.00flatN/AN/A$1K$17.42M0.00560EFTReFFECTOR TherapeuticsN/A$0.00flatN/A-99.5%$1KN/A0.0010ONCSQOncoSec MedicalN/AN/AN/AN/A$1KN/A0.0040ATNFW180 Life SciencesN/A$0.21-10.6%N/A+987.0%$0.00N/A0.007Positive NewsGap DownLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.00flatN/AN/A$0.00N/A0.002AIMDWAinosN/A$0.23-2.5%N/AN/A$0.00$110.87K0.0040Positive NewsGap Down Related Companies and Tools Related Companies AMPE Competitors HSTO Competitors PXMD Competitors CLVR Competitors EFTR Competitors ONCSQ Competitors ATNFW Competitors LBPSW Competitors AEHAW Competitors AIMDW Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CALA) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredNVDA: The cracks are beginning to showThe media hasn't caught up to the story yet, but when they do, this stock could leave Nvidia in the dust. I...InvestorPlace | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredUrgent: $3,452.50 a Month in Passive "AI Equity Checks"The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calithera Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calithera Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
